Search

Gregory Riggins Phones & Addresses

  • 1117 Bernoudy Rd, White Hall, MD 21161
  • Glendale, AZ
  • 813 Cedarcroft Rd, Baltimore, MD 21212 (302) 475-5483
  • 5234 Mission St #201, San Francisco, CA 94112
  • Timmonsville, SC
  • Decatur, GA
  • Durham, NC
  • Wilmington, DE

Work

Position: Medical Professional

Education

Degree: Graduate or professional degree

Resumes

Resumes

Gregory Riggins Photo 1

Gregory Riggins

View page
Location:
United States

Publications

Us Patents

Method For Distinguishing Follicular Thyroid Adenoma (Fta) From Follicular Thyroid Carcinoma (Ftc)

View page
US Patent:
7319011, Jan 15, 2008
Filed:
Apr 7, 2005
Appl. No.:
11/100640
Inventors:
Gregory J. Riggins - Baltimore MD,
Janete Cerruti - Moema,
Assignee:
Duke University - Durham NC
International Classification:
C12Q 1/00
G01N 1/70
G01N 33/567
G01N 33/574
US Classification:
435 71, 435 4, 435 21, 435 23
Abstract:
Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, C1orf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen.

Method For Distinguishing Follicular Thyroid Adenoma (Fta) From Follicular Thyroid Carcinoma (Ftc)

View page
US Patent:
7645590, Jan 12, 2010
Filed:
Dec 12, 2007
Appl. No.:
11/954661
Inventors:
Gregory J. Riggins - Baltimore MD,
Janete Cerruti - Sao Paulo,
Assignee:
Duke University - Durham NC
International Classification:
G01N 33/574
G01N 33/53
US Classification:
435 723, 435 71
Abstract:
Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, C1orf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen.

Method For Distinguishing Follicular Thyroid Adenoma (Fta) From Follicular Thyroid Carcinoma (Ftc)

View page
US Patent:
7927826, Apr 19, 2011
Filed:
Dec 29, 2009
Appl. No.:
12/648771
Inventors:
Gregory J. Riggins - Baltimore MD,
Janete Cerruti - Sao Paulo,
Assignee:
Duke University - Durham NC
International Classification:
G01N 33/574
G01N 33/53
C12Q 1/68
US Classification:
435 723, 435 6, 435 71
Abstract:
Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, C1orf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen.

Protein Markers For The Detection Of Thyroid Cancer Metastasis

View page
US Patent:
8394580, Mar 12, 2013
Filed:
Aug 18, 2008
Appl. No.:
12/222876
Inventors:
Gregory Riggins - Baltimore MD,
Janete Cerutti - Sao Paolo,
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/00
C12Q 1/68
G01N 33/48
G01N 33/53
G01N 33/567
G01N 33/574
G01N 1/00
US Classification:
435 4, 435 6, 435 71, 435 721, 435 723, 436 63, 436 64, 436174
Abstract:
This invention relates, e. g. , to a method for detecting the presence of lymph node metastases in a subject having papillary thyroid carcinoma (PTC), comprising measuring in a sample from the subject the amount of expression (e. g. , the amount of protein, or the amount of mRNA encoding the protein) of one or more of the following proteins: (a) LIMD2, and/or (b) PTPRC, and/or (c) LTB, and/or (d) CD48, and/or (e) ABCC3, wherein a significant amount of over-expression of one or more of protein(s) (a)-(e), compared to the baseline value, indicates that lymph node metastases are likely to be present in the subject.

Genetic Alterations In Isocitrate Dehydrogenase And Other Genes In Malignant Glioma

View page
US Patent:
2012020, Aug 9, 2012
Filed:
Mar 6, 2012
Appl. No.:
13/412696
Inventors:
Bert VOGELSTEIN - Baltimore MD,
Kenneth W. KINZLER - Baltimore MD,
D. Williams PARSONS - Bellaire TX,
Xiaosong ZHANG - Baltimore MD,
Jimmy Cheng-Ho LIN - Baltimore MD,
Rebecca J. LEARY - Baltimore MD,
Philipp ANGENENDT - Hamburg,
Nickolas PAPADOPOULOS - Towson MD,
Victor VELCULESCU - Dayton MD,
Giovanni PARMIGIANI - Boston MA,
Rachel KARCHIN - Towson MD,
Sian JONES - Baltimore MD,
Hai YAN - Chapel Hill NC,
Darell BIGNER - Mebane NC,
Chien-Tsun KUAN - Cary NC,
Gregory J. RIGGINS - White Hall MD,
Assignee:
DUKE UNIVERSITY - Durham SC
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C12Q 1/68
C07K 16/40
C07H 21/04
G01N 33/574
US Classification:
435 611, 435 612, 435 74, 5303898, 53038826, 5303873, 536 232
Abstract:
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.

Metabolic Inhibitor Against Tumors Having An Idh Mutation

View page
US Patent:
2013010, May 2, 2013
Filed:
May 10, 2011
Appl. No.:
13/697097
Inventors:
Gregory Joseph Riggins - White Hall MD,
Meghan Joyce Seltzer - Herndon VA,
Takashi Tsukamoto - Ellicott City MD,
Chi Van Dang - Penn Valley PA,
Ashkan Emadi - Bethesda MD,
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/433
A61K 31/704
US Classification:
514 34, 514363, 435375, 435 18
Abstract:
Methods for treating a cancer having a mutant isocitrate dehydrogenase (IDH), including, but not limited to, a malignant low-grade glioma, a secondary glioblastoma, a transforming myeloproliferative disorder (tMPD), and an acute myelogenous leukemia (AML), with a glutaminase inhibitor, including, bis--(-phenylacetamido--thiadiazol--yl)ethyl sulfide (BPTES), are disclosed.

Medulloblastoma Genes As Targets For Diagnosis And Therapeutics

View page
US Patent:
2013029, Nov 7, 2013
Filed:
Nov 8, 2011
Appl. No.:
13/884154
Inventors:
Bert Vogelstein - Baltimore MD,
Kenneth Kinzler - Baltimore MD,
Nickolas Papadopoulos - Towson MD,
Donald Williams Parsons - Bellaire TX,
Rebecca J. Leary - Baltimore MD,
Meng Li - San Francisco CA,
Xiaosong Zhang - San Francisco CA,
Sian Jones - Baltimore MD,
Gregory J. Riggins - White Hall MD,
Victor Velculescu - Dayton MD,
International Classification:
C12Q 1/68
US Classification:
514 44 R, 435 611, 435 71
Abstract:
Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis.

Mad-Related Genes In The Human

View page
US Patent:
6255464, Jul 3, 2001
Filed:
Apr 16, 1997
Appl. No.:
8/840767
Inventors:
Bert Vogelstein - Baltimore MD
Kenneth W. Kinzler - Belair MD
Gregory R. Riggins - Durham NC
Sam Thiagalingam - Baltimore MD
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C07H 2102
C07H 2104
C07K 100
US Classification:
536 231
Abstract:
Five human genes related to the Mad gene of Drosophila were identified. One of these genes (Smad2) was found to reside at chromosome 18q21, adjacent to a previously described member of this family called DPC4 (Smad4). Smad2 was found to be somatically mutated in two of eighteen human colorectal cancers. Smad2 and Smad4 are important in the suppression of neoplasia by mediating the growth inhibitory effects of TGF-. beta. -like ligands.
Gregory J Riggins from White Hall, MD, age ~60 Get Report